Squarepoint
RXRX icon

Squarepoint’s Recursion Pharmaceuticals RXRX Stock Holding History

Squarepoint’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-30,000
Closed -$159K – 4980
2025
Q1 		$159K Buy
+30,000
New +$219K ﹤0.01% 4096

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Squarepoint's RXRX Position: Q1 2026 in Review

Squarepoint reduced its Recursion Pharmaceuticals (RXRX) stake by 94% in Q1 2026, selling an estimated $3.22M and leaving 52,988 shares worth $163K. The position accounts for ﹤0.01% of the portfolio, ranked #3999.

Squarepoint first reported a position in RXRX in Q4 2021 and has held it in 12 quarters since. The position peaked at $3.63M in Q4 2025. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Squarepoint held 52,988 shares of Recursion Pharmaceuticals worth $163K as of Q1 2026.
  • Squarepoint sold 834,016 Recursion Pharmaceuticals shares in Q1 2026, an estimated $3.22M.
  • Recursion Pharmaceuticals made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #3999 holding.
  • Squarepoint first reported a position in Recursion Pharmaceuticals in Q4 2021 and has held it in 12 quarters since.
  • Squarepoint's Recursion Pharmaceuticals position peaked at $3.63M in Q4 2025.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.